# Treatment of Rett Syndrome With Recombinant Human IGF-1

> **NCT01777542** · PHASE2 · COMPLETED · sponsor: **Boston Children's Hospital** · enrollment: 30 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **DRUG:** Recombinant Human Insulin Growth Factor 1 (rhIGF-1)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01777542
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2016-07
- **Final completion:** 2016-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01777542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01777542, "Treatment of Rett Syndrome With Recombinant Human IGF-1". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01777542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*